Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…

Keith Westby Biography and Net Worth

COO of IVERIC bio

Keith Westby is Senior Vice President and Chief Operating Officer of Iveric Bio. Mr. Westby joined the Company in 2007 and has over 20 years of experience in program and strategic alliance management and manufacturing operations in biotechnology companies. Mr. Westby was most recently Senior Vice President, Development Operations. Prior to joining the Company, Mr. Westby worked at Pharmasset, Inc., as Director, Project and Alliance Management. He also served in positions of increasing responsibility at Eyetech Pharmaceuticals, including Director, Alliance & Project Management, leading multifunctional project teams in the New Drug Application filing and marketing approval of Macugen. Previously, Mr. Westby worked at Tunnell Consulting, where he was a Senior Consultant in the firm’s Life Sciences practice focused on manufacturing operations and process improvement. Mr. Westby holds a BS in applied physics from the State University of New York, College at Geneseo, a MS in engineering management from Drexel University, and a MBA degree from Columbia Business School.

What is Keith Westby's net worth?: The estimated net worth of Keith Westby is at least $1.58 million as of July 3rd, 2023. Mr. Westby owns 39,652 shares of IVERIC bio stock worth more than $1,584,097 as of April 20th. This net worth evaluation does not reflect any other assets that Mr. Westby may own. Additionally, Mr. Westby receives an annual salary of $701,680.00 as COO at IVERIC bio. Learn More about Keith Westby's net worth.
How old is Keith Westby?: Mr. Westby is currently 48 years old. There are 4 older executives and no younger executives at IVERIC bio. The oldest executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who is 67 years old. Learn More on Keith Westby's age.
What is Keith Westby's salary?: As the COO of IVERIC bio, Inc., Mr. Westby earns $701,680.00 per year. There are 4 executives that earn more than Mr. Westby. The highest earning executive at IVERIC bio is Mr. Glenn P. Sblendorio M.B.A., CEO & Director, who commands a salary of $1,360,000.00 per year. Learn More on Keith Westby's salary.
How do I contact Keith Westby?: The corporate mailing address for Mr. Westby and other IVERIC bio executives is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. IVERIC bio can also be reached via phone at (609) 474-6755 and via email at [email protected]. Learn More on Keith Westby's contact information.
Has Keith Westby been buying or selling shares of IVERIC bio?: Keith Westby has not been actively trading shares of IVERIC bio during the past quarter. Most recently, Keith Westby sold 20,000 shares of the business's stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $39.45, for a transaction totalling $789,000.00. Following the completion of the sale, the chief operating officer now directly owns 39,652 shares of the company's stock, valued at $1,564,271.40. Learn More on Keith Westby's trading history.
Who are IVERIC bio's active insiders?: IVERIC bio's insider roster includes David Carroll (CFO), Pravin Dugel (EVP), Anthony Gibney (EVP), Calvin Roberts (Director), Glenn Sblendorio (CEO), Christopher Simms (SVP), and Keith Westby (COO). Learn More on IVERIC bio's active insiders.
Are insiders buying or selling shares of IVERIC bio?: During the last year, insiders at the sold shares 8 times. They sold a total of 193,500 shares worth more than $6,752,270.65. The most recent insider tranaction occured on July, 3rd when COO Keith Westby sold 20,000 shares worth more than $789,000.00. Insiders at IVERIC bio own 2.7% of the company. Learn More about insider trades at IVERIC bio.
Information on this page was last updated on 7/3/2023.

Keith Westby Insider Trading History at IVERIC bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
7/3/2023	Sell	20,000	$39.45	$789,000.00	39,652
6/2/2023	Sell	20,000	$37.87	$757,400.00	39,652
5/1/2023	Sell	20,000	$37.12	$742,400.00	39,652
4/24/2023	Sell	18,782	$30.07	$564,774.74	39,652
4/21/2023	Sell	1,218	$30.00	$36,540.00	39,652
4/3/2023	Sell	40,000	$26.70	$1,068,000.00	39,652
3/2/2023	Sell	20,000	$23.93	$478,600.00	39,652
2/17/2023	Sell	15,000	$25.05	$375,750.00	46,354
1/3/2023	Sell	3,480	$20.06	$69,808.80	86,354
12/19/2022	Sell	6,740	$21.51	$144,977.40	81,084
12/12/2022	Sell	5,393	$20.89	$112,659.77	69,565
12/1/2022	Sell	10,030	$22.96	$230,288.80	59,759
11/1/2022	Sell	72,916	$23.92	$1,744,150.72	69,128
4/18/2022	Sell	10,000	$16.63	$166,300.00	99,128
4/5/2022	Sell	9,298	$19.02	$176,847.96	109,128
2/7/2022	Sell	10,000	$15.00	$150,000.00
1/3/2022	Sell	12,278	$16.39	$201,236.42
12/20/2021	Sell	4,516	$15.44	$69,727.04
12/13/2021	Sell	4,517	$14.74	$66,580.58
12/10/2021	Sell	3,614	$14.53	$52,511.42
12/10/2020	Sell	3,676	$6.96	$25,584.96
1/6/2020	Sell	293	$8.07	$2,364.51	41,276
12/13/2019	Sell	4,530	$6.60	$29,898.00	45,106

Keith Westby Buying and Selling Activity at IVERIC bio

IVERIC bio Company Overview

IVERIC bio, Inc., a biopharmaceutical company, focuses on the discovery and development of novel treatments for retinal diseases with unmet medical needs. The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD); and STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of autosomal recessive Stargardt disease. Its preclinical product candidatures include IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company also develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of avacincaptad pegol (ACP) administered as a monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of ACP administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. In addition, its minigene programs comprises miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related inherited retinal diseases (IRDs). The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey. As of July 11, 2023, IVERIC bio, Inc. operates as a subsidiary of Astellas US Holding, Inc.

Today's Range

Now: $39.95

$39.95

50 Day Range

MA: $38.88

$36.90

$39.95

2 Week Range

Now: $39.95

$9.39

$39.99

Volume

N/A

Average Volume

3,616,141 shs

Market Capitalization

$5.50 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.06

Your Money is Not Safe

From American Alternative | Ad

CLICK HERE TO GET YOUR GUIDE NOW

Keith Westby Biography and Net Worth

What is Keith Westby's net worth?

How old is Keith Westby?

What is Keith Westby's salary?

How do I contact Keith Westby?

Has Keith Westby been buying or selling shares of IVERIC bio?

Who are IVERIC bio's active insiders?

Are insiders buying or selling shares of IVERIC bio?

Keith Westby Insider Trading History at IVERIC bio

Keith Westby Buying and Selling Activity at IVERIC bio

IVERIC bio Company Overview

Today's Range

50 Day Range

2 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta